However, early phase clinical trials with RA in combination with tamoxifen did not improve patient outcomes and it has been postulated that RAR crosstalk with other receptors, including PR, may actually enrich the number of tumor cells with more aggressive properties [155,156]. This evidence concerns the gene PGR and neoplasm.